-
Healthnice Pharma Raises RMB100m to Expand Product Pipeline and R&D Team
•
China-based Nanjing Healthnice Pharmaceutical Technology Co., Ltd has reportedly raised RMB100 million (USD14.8 million) in another financing round. The round was led by CICC ChuanHua Industrial Equity Investment Fund, with other investors including Sunland Fund and Jiangxi State-owned Industry Development Fund. The proceeds will be used for product pipeline layout…
-
Healthnice Pharma Raises RMB100m to Expand Product Pipeline and R&D Team
•
China-based Nanjing Healthnice Pharmaceutical Technology Co., Ltd has reportedly raised RMB100 million (USD14.8 million) in another financing round. The round was led by CICC ChuanHua Industrial Equity Investment Fund, with other investors including Sunland Fund and Jiangxi State-owned Industry Development Fund. The proceeds will be used for product pipeline layout…
-
Gilead Transfers Trodelvy Asian Rights to Everest Medicines for USD280m
•
US pharmaceutical major Gilead Sciences Inc. (NASDAQ: GILD) today announced an agreement with Everest Medicines (HKG: 1952) to transfer the development and commercialization rights for Trodelvy (sacituzumab govitecan) in Asian territories. Trodelvy is a TROP-2 targeted antibody drug conjugate (ADC). The deal regains control of the drug’s Asian rights for…
-
CDE Prioritizes Review for Sanofi’s Nexviazyme and WinHealth’s Ravicti
•
The Center for Drug Evaluation (CDE) website indicates that two drugs have been selected for priority review status. The selected products are French giant Sanofi’s Nexviazyme (avalglucosidase alfa) and China-based Hong Kong WinHealth Pharma Group Ltd’s Ravicti (glycerol phenylbutyrate). Nexviazyme DetailsNexviazyme is an investigational enzyme replacement therapy (ERT) developed by…
-
Henlius Biotech’s HanBeiTai sBLA Accepted for HCC Treatment Review
•
Shanghai Henlius Biotech Inc. (HKG: 2696) announced that a supplementary Biologic License Application (sBLA) for its HanBeiTai, a biosimilar of Roche’s Avastin (bevacizumab), has been accepted for review by the Center for Drug Evaluation (CDE). The targeted indication is hepatocellular carcinoma (HCC). Drug BackgroundHanBeiTai is also awaiting a regulatory decision…
-
Alphamab Oncology Doses First Patient in KN046-209 Study for NSCLC
•
China-based Alphamab Oncology (HKG: 9966) announced the first patient dosing in the multi-center, open-label Phase II KN046-209 study. The trial evaluates the efficacy, safety, and tolerability of KN046 (erfonrilimab) combined with axitinib in first-line locally advanced or metastatic PD-L1-positive (TPS ≥ 1%) non-small cell lung cancer (NSCLC) patients who have…
-
Roche’s Rozlytrek Wins NMPA Approval for ROS1+ NSCLC Treatment
•
Swiss pharmaceutical giant Roche’s China unit announced that it has received market approval from the National Medical Products Administration (NMPA) for its drug Rozlytrek (entrectinib). The approved indication is for the treatment of ROS1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). Drug BackgroundEntrectinib, the first ROS1 inhibitor with…
-
EQRx Accelerates US Development of Two Chinese-Licensed Cancer Drugs
•
US-based pharma EQRx Inc. (Nasdaq: EQRX) has revealed its latest plans to accelerate the US market development of two innovative drugs licensed from Chinese partners. The company’s Q2 2022 financial report shows that a US-led Phase IIIb bridging study has recently been initiated for aumolertinib as a first-line treatment of…
